2018 | 2017 | 2016 | 2015
DateTitle 
April 13, 2018Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 13, 2018-- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its first quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, May 1, 2018. The schedule for the press release and conference call/webcast is as follows:       ... 
Printer Friendly Version
April 06, 2018Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Apr. 6, 2018-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252 study results evaluating Incyte’s epacadostat in combination with Merck’s KEYTRUDA® in patients with unresectable or metastatic melanoma determined that the study... 
Printer Friendly Version
March 15, 2018Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 15, 2018-- Incyte Corporation (Nasdaq:INCY) announces that 15 abstracts from its research and development portfolio will be presented at the upcoming 2018 American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018. These abstracts include the first pre-clinical data from the Company’s recently announced AXL/MER, TIM-3 and LAG-3 antibody programs in patients with advan... 
Printer Friendly Version
February 28, 2018Incyte Supports the Myeloproliferative Neoplasm Community in Honor of Rare Disease Day 2018
“Beyond Blue,” a short documentary by an award-winning filmmaker, debuts to raise awareness of MPNs MPN Heroes® 2018 nominations now open for submission WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 28, 2018-- Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURORDIS), and other rare disease health organizations and advocates in recognizing Rare Disease D... 
Printer Friendly Version
February 20, 2018Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 20, 2018-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 12:00 pm (EDT) in Boston; and Barclays Global Healthcare Conference on Wednesday, March 14, 2018 at 9:30 am (EDT) in Miami The... 
Printer Friendly Version
February 15, 2018Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs
Total revenues $444 million (+36%) in Q4 2017 and $1.54 billion (+39%) in FY 2017 Jakafi® (ruxolitinib) revenues $302 million (+27%) in Q4 2017 and $1.13 billion (+33%) in FY 2017; FY 2018 guidance $1.35-1.40 billion Significant progress in clinical development during 2017; portfolio now includes six later-stage product candidates Conference Call and Webcast Scheduled Today at 8:00 a.m. E... 
Printer Friendly Version
February 06, 2018Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 6, 2018-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 2018 RBC Capital Markets Global Healthcare Conference on Wednesday, February 21, 2018 at 11:00 am (ET) in New York. The presentation and Q&A session will be webcast live and can be accessed at www.incyte.com in the Investors section under “Events and Presentations.” Investors interested in listening to the live... 
Printer Friendly Version
January 31, 2018Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 31, 2018-- Incyte Corporation (Nasdaq:INCY) announced today an update to the conference call and webcast time for its fourth quarter and year end 2017 financial results to 8:00 a.m. ET on Thursday, February 15, 2018. The updated schedule for the press release and conference call/webcast is as follows:     ... 
Printer Friendly Version
January 24, 2018Incyte to Report Fourth Quarter and Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 24, 2018-- Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year end 2017 financial results conference call and webcast for 10:00 a.m. ET on Thursday, February 15, 2018. The schedule for the press release and conference call/webcast is as follows:      ... 
Printer Friendly Version
January 23, 2018Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 23, 2018-- Incyte Corporation (Nasdaq:INCY) today announced that it received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to 1,500,000 shares of Incyte’s common stock at a price of $88.88 per share in cash. TRC's offer price is approximately 4.59% lower than the $93.16 closing price of Incyte’s common stock on January 19, 2018, the last closing price prior to commence... 
Printer Friendly Version
January 08, 2018Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2018-- Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet